Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
NCT02496286
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
10
Enrollment
OTHER
Sponsor class
Stopped
Lack of Enrollment
Conditions
Malignant Ascites
Interventions
DRUG:
Intraperitoneal Bevacizumab
Sponsor
Eastern Regional Medical Center